Sickle Cell Gene Therapy: Can We Afford a Cure? | Dr. Russ Weiner
In Episode 4, (Part 2 of our conversation with Dr. Russ Weiner - a top scientific leader at Takeda), we boldly explore the Cell and Gene Therapy Industry, questioning its trajectory and potential impact on insurance companies.
Shifting focus, we delve into a groundbreaking Sickle Cell Therapy breakthrough, discussing its triumphs, challenges, and the crucial aspect of affordability. Despite the hurdles faced by payers and insurance companies, we find inspiration in the thrill of witnessing healing.
Discover the role of AAPS in shaping the biotech future and efforts to engage students. Episode…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.